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Introduction

Augustana College

Results – Aperio ImageScope
Figure 2. Graph of percent
CCR7 positivity. All samples
expressed CCR7 positivity in
the stroma or tumor (Median
=
44%).
However,
the
software did not discriminate
between tumor cells and
stromal cells, so many
samples expressing CCR7
did not actually contain
positive tumor cells (See
Figures 3A and 3B for
examples of false positives).

Inflammatory breast cancer (IBC) is a
rare form of breast cancer that is
characterized by breast skin changes,
such as changes in skin color, and
breast swelling caused by invasion of
tumor emboli into lymphatic vessels.
CCR7 is an immune cell receptor known
to be upregulated in IBC tumor cells that
is involved in immune cell movement into
lymphatics.
Our objective is to understand the
prevalence of CCR7 in IBC tissues and
identify its association with the presence
or absence of estrogen receptors (ER) in
order to understand its role in IBC
proliferation and potential novel
therapies.

Materials/Methods
A human tissue microarray (TMA) of 36
primary breast tissue biopsies from IBC
patients underwent immunohistochemical
staining for CCR7.
The stained TMA was converted to an eslide and analyzed for percent of positive
stain per sample using Aperio
ImageScope software. Positivity values
reflected total CCR7 presence throughout
the sample, including tumor and stromal
stain.

Figure 1. Example
of ImageScope
analysis on an 84%
positive sample.
Red indicates a
CCR7-positive area;
blue is negative.

In order to differentiate between positive
tumor and positive stroma, the TMA was
then reviewed by an expert pathologist,
where tissue cores containing tumor cells
(24 out of 36 samples) were evaluated for:
•
•
•
•

CCR7 positivity
Staining pattern
Percent tumor stained
Intensity

Results were interpreted alongside ER
status.

Figure 3A. Positive Stroma. No
tumor is present, making this a false
positive.

Figure 3B. Positive Mammary
Ducts. No tumor is present, making
this a false positive.

Results - Pathology

Figure 4A. Negative tumor.
Tumor cells are present, but
do not stain positive for
CCR7.

Figure 4B. Tumor cells are
CCR7
positive
with
complete
membranous
pattern, 3+ intensity, and
100% stain.

Figure 4C. Tumor cells are
CCR7
positive
with
incomplete
membranous
pattern, 3+ intensity, and
100% stain.

Pathology Data
CCR7 Positivity
Percent Tumor Stained
POS
23
100%
14
NEG
1
90%
2
80%
4
Pattern
50%
2
Complete Membranous
15
10%
1
Incomplete Membranous 8
Intensity
ER Status
2+
2
ER+
9
3+
21
ER8
Unknown
6
Table 1. CCR7 pathology results and ER status data for all
tumor-containing samples. 23 samples had CCR7 tumor
positivity, of which 65% had complete membranous pattern, 91%
had 3+ intensity, and 61% had 100% tumor stain. Approximately
half of the samples with known ER data were ER positive.

Next Steps
CCR7 was highly expressed in 96% of
tumor-containing samples, including both
ER+ and ER- subtypes. Thus, it can be
further studied for future personalized IBC
treatments. Additionally, since all samples
lacking tumors still exhibited CCR7
positivity in the stroma, the effect of
stromal CCR7 on IBC development must
be further explored.
Further analysis includes obtaining data
for the samples of unknown ER status in
this study, as well as HER2 data. Future
repeated studies should include patients
for whom we have medical images for
comparison with CCR7 pathology, as
CCR7 may influence IBC clinical
presentation.

Conclusions
Since CCR7 is present in nearly all cases
of IBC, including both ER+ and ERsubtypes, it should be further studied as a
target for future personalized IBC
treatments.
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